Inhibiting CTRP5 Action to Improve Insulin Resistance Associated with Obesity and Type 2 Diabetes

Case ID:
Disclosure Date:
Unmet Need
Obesity is a leading preventable cause of death worldwide, with increasing rates in adults and children. In 2014, 600 million adults (13%) and 42 million children under the age of five were obese.  Obesity is associated with a number of comorbidities, the most common of which is metabolic syndrome, a combination of medical disorders which includes: diabetes mellitus type 2, high blood pressure, high blood cholesterol, and high triglyceride levels.  Authorities view it as one of the most serious public health problems of the 21st century.  Unfortunately, few targets have been identified that are amenable for the development of obesity and metabolic disease therapeutics.
Technology Overview
JHU researchers identified a secreted protein of the C1q family, CTRP5, which was markedly upregulated in obese and diabetic humans and rodent models of obesity.  Using genetic loss of function studies in mouse, they demonstrated that CTRP5-deficient mice had reduced fasting insulin but were otherwise comparable to wild-type littermate controls in body weight and adiposity. However, when fed a high-fat diet, CTRP5-deficient animals had reduced food intake, attenuated hepatic steatosis, and improved insulin action. Loss of CTRP5 also improved the capacity of chow-fed aged mice to respond to subsequent high-fat feeding, as evidenced by decreased insulin resistance. The data provide strong evidence that CTRP5 is a negative regulator of glucose metabolism and insulin sensitivity and inhibition of CTRP5 action may result in the alleviation of insulin resistance associated with obesity and diabetes.
Stage of Development
The researchers have preclinical data and continue to investigate the role of CTRP5 in metabolic homeostasis.
Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11)
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Inhibiting CTRP5 Action to Improve Insulin Resistance Associated with Obesity and Type 2 Diabetes PCT: Patent Cooperation Treaty United States 15/745,625 1/17/2018     Pending
For Information, Contact:
Vera Sampels
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum